Our study revealed that elevated AIP levels significantly increased the risk of CCS in NAFLD patients, even after adjusting for traditional confounders, providing new evidence for the clinical application of AIP as a CCS risk assessment biomarker. The gene discussed is AIP; the disease is metabolic dysfunction-associated steatotic liver disease.